Harvoni

Two drugs that account for more than half of Gilead Sciences, Inc.'s (NASDAQ: GILD) sales may also cause abnormally slow heartbeats, according to a warning sent by the company on Friday. Shares of Gilead were lower by more than 3 percent in pre-market trading. According to the warning,...

Geoffrey Meacham of Barclays initiated coverage of Gilead Sciences, Inc. (NASDAQ: GILD) on Tuesday with an Overweight rating and $125 price target. According to Meacham, Gilead Sciences' will likely see “dramatic growth” in hepatitis C that should drive upside in 2015 and beyond. Specifically, the...